A photo of Robert Lorsbach.

Staff Pathologist, Division of Pathology

Director, Hematopathology

Professor, UC Department of Pathology and Laboratory Medicine

513-636-4261

Board Certified

"I always remember that there's a patient and family on "the other side" of every biopsy and pathology case that I evaluate. I strive to apply the same rigor and thoroughness in my evaluation and diagnosis of cases that I would expect if the biopsy was for one of my own children."

My Biography & Research

Biography

I’m a hematopathologist, the branch of pathology concerned with diseases of the blood and blood formation (hematopoiesis). Even though our patients don't usually meet us, I would like them to know that Cincinnati Children’s pathologists are incredibly dedicated and work diligently to provide the best possible pathology and laboratory services for our patients.

Hematopathology merges my research interests in the biological aspects of hematopoiesis and cancer with my desire to provide clinical colleagues with the most accurate pathologic diagnoses possible and give patients the best clinical care possible.

I don't usually directly interact with our patients. Nevertheless, I always remember that there's a patient and family on "the other side" of every biopsy and pathology case that I evaluate. I strive to apply the same rigor and thoroughness in my evaluation and diagnosis of cases that I would expect if the biopsy was for one of my own children.

My research is translational and directed toward improving our diagnostic accuracy and understanding of hematologic diseases and cancer.

When I'm not at the hospital, I love being outdoors. Gardening, planting trees and hiking with my daughters is what I enjoy most.

Academic Affiliation

Professor, UC Department of Pathology and Laboratory Medicine

Clinical Divisions

Pathology

Research Divisions

Pathology

My Education

MD: University of Kansas, Lawrence, KS, 1994.

PhD: Experimental Pathology, University of Kansas, Lawrence, KS, 1995.

My Publications

Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency. Wortmann, SB; Zietkiewicz, S; Guerrero-Castillo, S; Feichtinger, RG; Wagner, M; Russell, J; Ellaway, C; Mróz, D; Wyszkowski, H; Weis, D; et al. Genetics in Medicine. 2021.

Infantile leukemia-What factors determine its distinct biological nature? Clinicopathological study of 78 cases. Liu, X; Zhao, Y; Luedke, C; Jug, R; Yang, LH; Lu, M; Pan, Z; Wang, D; Lorsbach, R; Shi, Y; et al. International Journal of Laboratory Hematology. 2021.

Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Niss, O; Lorsbach, RB; Berger, M; Chonat, S; McLemore, M; Buchbinder, D; McCavit, T; Shaffer, LG; Simpson, J; Schwartz, JH; et al. Blood Cells, Molecules, and Diseases. 2021; 87.

VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Seu, KG; Trump, LR; Emberesh, S; Lorsbach, RB; Johnson, C; Meznarich, J; Underhill, HR; Chou, ST; Sakthivel, H; Nassar, NN; et al. American Journal of Human Genetics. 2020; 107:1149-1156.

High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy. Lee, LH; Krupski, C; Clark, J; Wunderlich, M; Lorsbach, RB; Grimley, MS; Burwinkel, M; Nelson, A; Kumar, AR. Blood Advances. 2020; 4:717-727.

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Niss, O; Lorsbach, RB; Buchbinder, DK; Chonat, S; McLemore, ML; McCavit, T; Schwartz, JH; Meznarich, J; Seu, K; Zhang, W; et al. Blood. 2019; 134:3521-3521.

Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study. Sopfe, J; Endres, A; Campbell, K; Hayes, K; Trout, AT; Liang, X; Lorsbach, R; O'Brien, MM; Cost, CR. Pediatric Blood and Cancer. 2019; 66.

Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study. Knez, V; Liu, X; Schowinsky, J; Pan, Z; Wang, D; Lorsbach, R; Lu, C; Luedke, C; Haag, M; Carstens, B; et al. Leukemia and Lymphoma. 2019; 60:1006-1013.

Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Gurunathan, A; Boucher, AA; Mark, M; Prus, KM; O'Brien, MM; Breese, EH; Mizukawa, BE; Absalon, MJ; Nelson, AS; Jordan, MB; et al. Pediatric Blood and Cancer. 2018; 65.

Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. Lee, LH; Gasilina, A; Roychoudhury, J; McCormack, FX; Pressey, J; Grimley, MS; Lorsbach, R; Ali, S; Bailey, M; Stephens, P; et al. JCI insight. 2017; 2.